晚期非小细胞肺癌免疫治疗中ctDNA的动态监测的现状与未来
Status and Future of ctDNA Dynamic Monitoring in Immunotherapy for Advanced Non-Small Cell Lung Cancer
DOI: 10.12677/ACM.2023.1361476, PDF,    科研立项经费支持
作者: 葛 倩：西安医学院研究生院，陕西 西安；赵 征*, 李索尼：陕西省肿瘤医院内科，陕西 西安；张志芸：陕西中医药大学研究生院，陕西 咸阳
关键词: 晚期非小细胞肺癌；免疫治疗；ctDNA；动态监测；Advanced Non-Small Cell Lung Cancer； Immunotherapy； ctDNA； Dynamic Monitoring
摘要: 非小细胞肺癌仍然是全球对人类危害最大的疾病之一，免疫治疗自问世就给晚期非小细胞肺癌患者带来了前所未有的益处。免疫治疗虽然在大跨步的飞速发展，但是仍然有一部分人无法获益，一种可靠且易于重复检测的判断疗效方法则显得尤为重要。ctDNA检测作为一种非侵入性检查，具有易于重复操作、特异性较强的优势，在不同类型肿瘤中的价值被普遍认可。ctDNA的动态监测也对免疫治疗过程中疗效的评估以及预后的发展发挥着十分重要的作用。与此同时，ctDNA在监测过程中的检测时间点、量化标准、各个检测方法的共识有待也进一步商榷。
Abstract: Non-small cell lung cancer remains one of the most dangerous diseases in the world. Immunother-apy has brought unprecedented benefits to patients with advanced non-small cell lung cancer since its introduction. Despite the rapid development of immunotherapy in great strides, there are still some people who cannot benefit from it. Therefore, a reliable and easy to repeat detection method to judge the efficacy is particularly important. ctDNA testing is a non-invasive, easy to perform and reproducible method, which is widely recognized for its value in different types of tumors. Dynamic monitoring of ctDNA is also very important for evaluating the efficacy and predicting the prognosis during immunotherapy. At the same time, the detection time point of ctDNA in the longitudinal process, the quantitative standard and the consensus of each detection method need to be further discussed.
文章引用：葛倩, 赵征, 李索尼, 张志芸. 晚期非小细胞肺癌免疫治疗中ctDNA的动态监测的现状与未来[J]. 临床医学进展, 2023, 13(6): 10554-10559. https://doi.org/10.12677/ACM.2023.1361476

参考文献

[1] Siegel, R.L., Miller, K.D., Wagle, N.S. and Jemal, A. (2023) Cancer Statistics, 2023. CA: A Cancer Journal for Clini-cians, 73, 17-48. [Google Scholar] [CrossRef] [PubMed]
[2] He, T., Cao, J., Xu, J., Lv, W. and Hu, J. (2020) Mini-mally Invasive Therapies for Early Stage Non-Small Cell Lung Cancer. Chinese Journal of Lung Cancer, 23, 479-486.
[3] Lin, C., Liu, X., Zheng, B., Ke, R. and Tzeng, C.M. (2021) Liquid Biopsy, ctDNA Diagnosis through NGS. Life (Basel), 11, Article No. 890. [Google Scholar] [CrossRef] [PubMed]
[4] Chae, Y.K. and Oh, M.S. (2019) Detection of Minimal Residual Disease Using ctDNA in Lung Cancer: Current Evidence and Future Directions. Journal of Thoracic Oncology, 14, 16-24. [Google Scholar] [CrossRef] [PubMed]
[5] Papadopoulos, N. (2020) Patho-physiology of ctDNA Release into the Circulation and Its Characteristics: What Is Important for Clinical Applications. Recent Results in Cancer Research, 215, 163-180. [Google Scholar] [CrossRef] [PubMed]
[6] Pai-Scherf, L., Blumenthal, G.M., Li, H., et al. (2017) FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond. Oncologist, 22, 1392-1399. [Google Scholar] [CrossRef] [PubMed]
[7] Tang, S., Qin, C., Hu, H., et al. (2022) Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects. Cells (Basel), 11, Article No. 320. [Google Scholar] [CrossRef] [PubMed]
[8] Mandel, P. and Metais, P. (1948) Nuclear Acids in Human Blood Plasma. Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales, 142, 241-243.
[9] Horndalsveen, H., Alver, T.N., Dalsgaard, A.M., et al. (2023) Atezolizumab and Stereotactic Body Radiotherapy in Patients with Advanced Non-Small Cell Lung Cancer: Safety, Clinical Activity and ctDNA Responses—The ComIT-1 Trial. Molecular Oncology, 17, 487-498. [Google Scholar] [CrossRef] [PubMed]
[10] Pessoa, L.S., Heringer, M. and Ferrer, V.P. (2020) ctDNA as a Cancer Biomarker: A Broad Overview. Critical Reviews in Oncology/Hematology, 155, Article ID: 103109. [Google Scholar] [CrossRef] [PubMed]
[11] Wu, N., Zhang, Z., Zhou, X., et al. (2020) Mutational Land-scape and Genetic Signatures of Cell-Free DNA in Tumour-Induced Osteomalacia. Journal of Cellular and Molecular Medicine, 24, 4931-4943. [Google Scholar] [CrossRef] [PubMed]
[12] Vu, P., Khagi, Y., Riviere, P., Goodman, A. and Kurzrock, R. (2020) Total Number of Alterations in Liquid Biopsies Is an Independent Predictor of Survival in Patients with Advanced Can-cers. JCO Precision Oncology, 4. [Google Scholar] [CrossRef] 
[13] Lakhotia, R., Melani, C., Dunleavy, K., et al. (2022) Circulating Tumor DNA Predicts Therapeutic Outcome in Mantle Cell Lymphoma. Blood Advances, 6, 2667-2680. [Google Scholar] [CrossRef] [PubMed]
[14] Slagter, A.E., Vollebergh, M.A., Caspers, I.A., et al. (2022) Prognostic Value of Tumor Markers and ctDNA in Patients with Resectable Gastric Cancer Receiving Periopera-tive Treatment: Results from the CRITICS Trial. Gastric Cancer, 25, 401-410. [Google Scholar] [CrossRef] [PubMed]
[15] Mencel, J., Slater, S., Cartwright, E. and Starling, N. (2022) The Role of ctDNA in Gastric Cancer. Cancers, 14, Article No. 5105. [Google Scholar] [CrossRef] [PubMed]
[16] Zhang, Z., Wu, H., Chong, W., Shang, L., Jing, C. and Li, L. (2022) Liquid Biopsy in Gastric Cancer: Predictive and Prognostic Biomarkers. Cell Death & Disease, 13, Article No. 903. [Google Scholar] [CrossRef] [PubMed]
[17] Hamakawa, T., Kukita, Y., Kurokawa, Y., et al. (2015) Moni-toring Gastric Cancer Progression with Circulating Tumour DNA. British Journal of Cancer, 112, 352-356. [Google Scholar] [CrossRef] [PubMed]
[18] Masfarre, L., Vidal, J., Fernandez-Rodriguez, C. and Montagut, C. (2021) ctDNA to Guide Adjuvant Therapy in Localized Colorectal Cancer (CRC). Cancers, 13, Article No. 2869. [Google Scholar] [CrossRef] [PubMed]
[19] Osumi, H., Shinozaki, E., Yamaguchi, K. and Zembutsu, H. (2019) Clinical Utility of Circulating Tumor DNA for Colorectal Cancer. Cancer Science, 110, 1148-1155. [Google Scholar] [CrossRef] [PubMed]
[20] Chakrabarti, S., Kasi, A.K., Parikh, A.R. and Mahipal, A. (2022) Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)-Guided Minimal Residual Disease (MRD) As-sessment in Colorectal Cancer (CRC). Cancers, 14, Article No. 3078. [Google Scholar] [CrossRef] [PubMed]
[21] Sant, M., Bernat-Peguera, A., Felip, E. and Margeli, M. (2022) Role of ctDNA in Breast Cancer. Cancers, 14, Article No. 310. [Google Scholar] [CrossRef] [PubMed]
[22] Tzanikou, E. and Lianidou, E. (2020) The Potential of ctDNA Analysis in Breast Cancer. Critical Reviews in Clinical Laboratory Sciences, 57, 54-72. [Google Scholar] [CrossRef] [PubMed]
[23] Ma, F., Guan, Y., Yi, Z., et al. (2020) Assessing Tumor Heterogeneity Using ctDNA to Predict and Monitor Therapeutic Response in Metastatic Breast Cancer. International Journal of Cancer, 146, 1359-1368. [Google Scholar] [CrossRef] [PubMed]
[24] Goldberg, S.B., Narayan, A., Kole, A.J., et al. (2018) Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA. Clinical Cancer Research, 24, 1872-1880. [Google Scholar] [CrossRef] 
[25] Lipson, E.J., Velculescu, V.E., Pritchard, T.S., et al. (2014) Circulating Tumor DNA Analysis as a Real-Time Method for Monitoring Tumor Burden in Melanoma Patients Under-going Treatment with Immune Checkpoint Blockade. The Journal for ImmunoTherapy of Cancer, 2, Article No. 42. [Google Scholar] [CrossRef] [PubMed]
[26] Singh, A.P., Cheng, H., Guo, X., Levy, B. and Halmos, B. (2017) Circulating Tumor DNA in Non-Small-Cell Lung Cancer: A Primer for the Clinician. JCO Precision Oncology, 1, 1-13. [Google Scholar] [CrossRef] 
[27] Li, L., Zhang, J., Jiang, X. and Li, Q. (2018) Promising Clinical Appli-cation of ctDNA in Evaluating Immunotherapy Efficacy. American Journal of Cancer Research, 8, 1947-1956.
[28] Bergerot, P.G., Hahn, A.W., Bergerot, C.D., Jones, J. and Pal, S.K. (2018) The Role of Circulating Tumor DNA in Renal Cell Carcinoma. Current Treatment Options in Oncology, 19, Article No. 10. [Google Scholar] [CrossRef] [PubMed]
[29] Garon, E.B., Rizvi, N.A., Hui, R., et al. (2015) Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 372, 2018-2028. [Google Scholar] [CrossRef] 
[30] Robert, C., Long, G.V., Brady, B., et al. (2015) Nivolumab in Pre-viously Untreated Melanoma without BRAF Mutation. The New England Journal of Medicine, 372, 320-330. [Google Scholar] [CrossRef] 
[31] Gouda, M.A., Huang, H.J., Piha-Paul, S.A., et al. (2022) Longitu-dinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers. JCO Precision On-cology, 6, e2100512. [Google Scholar] [CrossRef] 
[32] van der Leest, P., Hiddinga, B., Miedema, A., et al. (2021) Circulating Tumor DNA as a Biomarker for Monitoring Early Treatment Responses of Patients with Advanced Lung Adenocarci-noma Receiving Immune Checkpoint Inhibitors. Molecular Oncology, 15, 2910-2922. [Google Scholar] [CrossRef] [PubMed]
[33] Bardelli, A. and Pantel, K. (2017) Liquid Biopsies, What We Do Not Know (Yet). Cancer Cell, 31, 172-179. [Google Scholar] [CrossRef] [PubMed]
[34] Nikanjam, M., Kato, S. and Kurzrock, R. (2022) Liquid Biopsy: Current Technology and Clinical Applications. Journal of Hematology Oncology, 15, Article No. 131. [Google Scholar] [CrossRef] [PubMed]
[35] Zhou, H., Zhu, L., Song, J., et al. (2022) Liquid Biopsy at the Frontier of Detection, Prognosis and Progression Monitoring in Colorectal Cancer. Molecular Cancer, 21, Article No. 86. [Google Scholar] [CrossRef] [PubMed]
[36] Spoor, J., Eyck, B.M., Atmodimedjo, P.N., et al. (2021) Liquid Biopsy in Esophageal Cancer: A Case Report of False-Positive Circulating Tumor DNA Detection Due to Clonal Hema-topoiesis. Annals of Translational Medicine, 9, Article No. 1264. [Google Scholar] [CrossRef] [PubMed]
[37] Salfer, B., Li, F., Wong, D. and Zhang, L. (2022) Urinary Cell-Free DNA in Liquid Biopsy and Cancer Management. Clinical Chemistry, 68, 1493-1501. [Google Scholar] [CrossRef] [PubMed]
[38] Yu, H., Han, L., Yuan, J. and Sun, Y. (2020) Circulating Tumor Cell Free DNA from Plasma and Urine in the Clinical Management of Colorectal Cancer. Cancer Biomarkers, 27, 29-37. [Google Scholar] [CrossRef] 

为你推荐